SE8205892D0
(sv)
|
1982-10-18 |
1982-10-18 |
Bror Morein |
Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
|
ATE67769T1
(de)
|
1983-01-25 |
1991-10-15 |
Ciba Geigy Ag |
Neue peptidderivate.
|
IL73534A
(en)
|
1983-11-18 |
1990-12-23 |
Riker Laboratories Inc |
1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
|
US4680338A
(en)
|
1985-10-17 |
1987-07-14 |
Immunomedics, Inc. |
Bifunctional linker
|
US5057540A
(en)
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
US5238944A
(en)
|
1988-12-15 |
1993-08-24 |
Riker Laboratories, Inc. |
Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
|
US4929624A
(en)
|
1989-03-23 |
1990-05-29 |
Minnesota Mining And Manufacturing Company |
Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
|
JPH0832638B2
(ja)
|
1989-05-25 |
1996-03-29 |
カイロン コーポレイション |
サブミクロン油滴乳剤を含んで成るアジュバント製剤
|
US4988815A
(en)
|
1989-10-26 |
1991-01-29 |
Riker Laboratories, Inc. |
3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
|
WO1992015582A1
(en)
|
1991-03-01 |
1992-09-17 |
Minnesota Mining And Manufacturing Company |
1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES
|
US5389640A
(en)
|
1991-03-01 |
1995-02-14 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
US5268376A
(en)
|
1991-09-04 |
1993-12-07 |
Minnesota Mining And Manufacturing Company |
1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
US5266575A
(en)
|
1991-11-06 |
1993-11-30 |
Minnesota Mining And Manufacturing Company |
2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
|
IL105325A
(en)
|
1992-04-16 |
1996-11-14 |
Minnesota Mining & Mfg |
Immunogen/vaccine adjuvant composition
|
US5395937A
(en)
|
1993-01-29 |
1995-03-07 |
Minnesota Mining And Manufacturing Company |
Process for preparing quinoline amines
|
WO1994021292A1
(en)
|
1993-03-23 |
1994-09-29 |
Smithkline Beecham Biologicals (S.A.) |
Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
|
CZ288182B6
(en)
|
1993-07-15 |
2001-05-16 |
Minnesota Mining & Mfg |
Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon
|
US5352784A
(en)
|
1993-07-15 |
1994-10-04 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
AU5543294A
(en)
|
1993-10-29 |
1995-05-22 |
Pharmos Corp. |
Submicron emulsions as vaccine adjuvants
|
GB9326174D0
(en)
|
1993-12-22 |
1994-02-23 |
Biocine Sclavo |
Mucosal adjuvant
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6429199B1
(en)
|
1994-07-15 |
2002-08-06 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules for activating dendritic cells
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
AUPM873294A0
(en)
|
1994-10-12 |
1994-11-03 |
Csl Limited |
Saponin preparations and use thereof in iscoms
|
US5482936A
(en)
|
1995-01-12 |
1996-01-09 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-C]quinoline amines
|
UA56132C2
(ru)
|
1995-04-25 |
2003-05-15 |
Смітклайн Бічем Байолоджікалс С.А. |
Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины
|
EP1005368B1
(en)
|
1997-03-10 |
2009-09-02 |
Ottawa Hospital Research Institute |
Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
|
US6818222B1
(en)
|
1997-03-21 |
2004-11-16 |
Chiron Corporation |
Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
|
PL190237B1
(pl)
*
|
1997-04-01 |
2005-11-30 |
Corixa Corp |
Kompozycja adiuwantowa, szczepionka, sposób wytwarzania kompozycji adiuwantowej oraz zastosowanie
|
US6080725A
(en)
|
1997-05-20 |
2000-06-27 |
Galenica Pharmaceuticals, Inc. |
Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
|
US6562798B1
(en)
|
1998-06-05 |
2003-05-13 |
Dynavax Technologies Corp. |
Immunostimulatory oligonucleotides with modified bases and methods of use thereof
|
US6110929A
(en)
|
1998-07-28 |
2000-08-29 |
3M Innovative Properties Company |
Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
|
GB9817052D0
(en)
|
1998-08-05 |
1998-09-30 |
Smithkline Beecham Biolog |
Vaccine
|
EP2266604A3
(en)
|
1998-10-16 |
2011-05-11 |
GlaxoSmithKline Biologicals S.A. |
Adjuvant systems and vaccines
|
WO2000022972A1
(fr)
|
1998-10-22 |
2000-04-27 |
Yosuke Naito |
Pomme de douche
|
US20030130212A1
(en)
|
1999-01-14 |
2003-07-10 |
Rossignol Daniel P. |
Administration of an anti-endotoxin drug by intravenous infusion
|
US6551600B2
(en)
|
1999-02-01 |
2003-04-22 |
Eisai Co., Ltd. |
Immunological adjuvant compounds compositions and methods of use thereof
|
PT1150918E
(pt)
|
1999-02-03 |
2005-01-31 |
Biosante Pharmaceuticals Inc |
Metodo de fabrico de particulas terapeuticas de fosfato de calcio
|
US6331539B1
(en)
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
ATE384072T1
(de)
|
2000-09-26 |
2008-02-15 |
Idera Pharmaceuticals Inc |
Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
|
US6667312B2
(en)
|
2000-12-08 |
2003-12-23 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6660747B2
(en)
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US6664264B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6660735B2
(en)
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Urea substituted imidazoquinoline ethers
|
US6664260B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Heterocyclic ether substituted imidazoquinolines
|
UA75622C2
(en)
|
2000-12-08 |
2006-05-15 |
3M Innovative Properties Co |
Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
|
US6677348B2
(en)
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Aryl ether substituted imidazoquinolines
|
US6677347B2
(en)
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
US6664265B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
WO2003035836A2
(en)
|
2001-10-24 |
2003-05-01 |
Hybridon Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
|
US6677349B1
(en)
|
2001-12-21 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
AU2003233519A1
(en)
|
2002-05-29 |
2003-12-19 |
3M Innovative Properties Company |
Process for imidazo(4,5-c)pyridin-4-amines
|
EP1742659B1
(en)
|
2004-04-05 |
2013-03-13 |
Pah Usa 15 Llc |
Microfluidized oil-in-water emulsions and vaccine compositions
|
AU2005333603A1
(en)
*
|
2004-10-21 |
2007-01-04 |
Wyeth |
Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
|
US20060228369A1
(en)
|
2005-04-11 |
2006-10-12 |
Program For Appropriate Technology In Health |
Stabilization and preservation of temperature-sensitive vaccines
|
US7691368B2
(en)
|
2005-04-15 |
2010-04-06 |
Merial Limited |
Vaccine formulations
|
US8703095B2
(en)
|
2005-07-07 |
2014-04-22 |
Sanofi Pasteur S.A. |
Immuno-adjuvant emulsion
|
TWI382019B
(zh)
|
2005-08-19 |
2013-01-11 |
Array Biopharma Inc |
作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯
|
GB0526038D0
(en)
|
2005-12-21 |
2006-02-01 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
FR2896162B1
(fr)
|
2006-01-13 |
2008-02-15 |
Sanofi Pasteur Sa |
Emulsion huile dans eau thermoreversible
|
CA2655133C
(en)
|
2006-06-12 |
2018-03-20 |
Nabi Biopharmaceuticals |
Use of alpha-toxin for treating and preventing staphylococcus infections
|
WO2008005555A1
(en)
|
2006-07-07 |
2008-01-10 |
Gilead Sciences, Inc. |
Modulators of toll-like receptor 7
|
DK2086582T3
(da)
|
2006-10-12 |
2013-02-04 |
Glaxosmithkline Biolog Sa |
Vaccine omfattende en olie-i-vand-emulsionsadjuvans
|
US20090007256A1
(en)
|
2007-06-28 |
2009-01-01 |
Microsoft Corporation |
Using a trusted entity to drive security decisions
|
JP5658564B2
(ja)
|
2007-08-31 |
2015-01-28 |
ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago |
ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
|
PE20091236A1
(es)
|
2007-11-22 |
2009-09-16 |
Astrazeneca Ab |
Derivados de pirimidina como immunomoduladores de tlr7
|
NZ588191A
(en)
|
2008-03-03 |
2012-06-29 |
Irm Llc |
Compounds and compositions as tlr activity modulators
|
NZ599446A
(en)
|
2008-03-24 |
2013-11-29 |
4Sc Discovery Gmbh |
Novel substituted imidazoquinolines
|
DK2313111T3
(da)
|
2008-08-01 |
2013-12-02 |
Ventirx Pharmaceuticals Inc |
Toll-lignende receptoragonistformuleringer og anvendelse deraf
|
EP2208787A1
(en)
*
|
2009-01-19 |
2010-07-21 |
Université de Liège |
A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
|
BRPI1010307B1
(pt)
*
|
2009-04-03 |
2021-07-27 |
University Of Chicago |
Polipeptídeos variantes de proteína a (spa), composição imunogênica compreendendo os mesmos, vacina, método de produção da referida vacina, bem como uso dos referidos polipeptídeos
|
NZ612315A
(en)
|
2009-04-14 |
2014-10-31 |
Novartis Ag |
Compositions for immunising against staphylococcus aureus
|
ES2443952T3
(es)
|
2009-09-02 |
2014-02-21 |
Novartis Ag |
Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
|
JP2013523818A
(ja)
*
|
2010-04-05 |
2013-06-17 |
ザ・ユニバーシティー・オブ・シカゴ |
免疫反応のエンハンサーとしてのプロテインA(SpA)抗体に関連する組成物および方法
|
JP2013538217A
(ja)
|
2010-09-01 |
2013-10-10 |
ノバルティス アーゲー |
不溶性金属塩への免疫増強物質の吸着
|
US9095540B2
(en)
*
|
2010-09-09 |
2015-08-04 |
The University Of Chicago |
Methods and compositions involving protective staphylococcal antigens
|
CA2847204A1
(en)
|
2011-09-01 |
2013-03-07 |
Novartis Ag |
Adjuvanted formulations of staphylococcus aureus antigens
|
US20150044251A1
(en)
|
2011-12-23 |
2015-02-12 |
Novartis Ag |
Stable compositions for immunising against staphylococcus aureus
|
CA2865759C
(en)
|
2012-03-07 |
2020-07-21 |
Novartis Ag |
Immunologically useful arginine salts
|
CN104159602B
(zh)
|
2012-03-08 |
2017-10-24 |
葛兰素史密丝克莱恩生物有限公司 |
加强疫苗的含佐剂制剂
|
US20150202277A1
(en)
|
2012-08-31 |
2015-07-23 |
Novartis Ag |
Stabilised proteins for immunising against staphylococcus aureus
|
TR201910573T4
(tr)
|
2012-08-31 |
2019-08-21 |
Glaxosmithkline Biologicals Sa |
Staphylococcus aureus'a karşı bağışıklık kazandırmak için stabilize edilmiş proteinler.
|
WO2014033193A1
(en)
*
|
2012-08-31 |
2014-03-06 |
Novartis Ag |
Stabilised proteins for immunising against staphylococcus aureus
|
JP2015528456A
(ja)
|
2012-08-31 |
2015-09-28 |
ノバルティス アーゲー |
Staphylococcusaureusに対する免疫化のための安定化されたタンパク質
|
CN103694322B
(zh)
*
|
2013-12-09 |
2016-08-17 |
成都欧林生物科技股份有限公司 |
金黄色葡萄球菌SpA5突变体及其制备方法和应用
|
CN103645318B
(zh)
*
|
2013-12-09 |
2016-11-02 |
成都欧林生物科技股份有限公司 |
金黄色葡萄球菌SpA5突变体抗原特异性IgG抗体检测方法和检测试剂盒
|